Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients☆
Background/Aims
Autoimmune Hepatitis (AIH) is a liver disease which may lead to liver cirrhosis. Cirrhosis is a well-known risk factor for hepatocellular cancer. Lymphoma is a disease, where immune modulating drugs as well as the autoimmune disease itself may contribute to the elevated risk. The aim was to investigate the risks of malignancies in a large cohort of AIH patients.
Methods
Four hundred and seventy-three patients with AIH were matched to the Swedish national cancer register as well as to the death cause register.
Results
We found an overall higher risk of malignancies in the cohort of AIH patients from the date of diagnosis with a SIR of 1.51 (95% CI 1.10–2.03). SIR in the subpopulation of well defined catchment areas and complete case finding was 23.28 (95% CI 7.5–54.34) for HCC. Lymphomas were found a SIR of 13.09 (95% CI 4.22–30.56).
Conclusions
There was an overall increased risk of malignancies in a cohort of AIH patients, which manly was caused by hepatobiliary cancers. However, the true risk of HCC in an AIH cirrhotic cohort has yet to be investigated. A significantly higher risk of lymphomas was also found, but no clear cut association to the use of immune modulators.
Keywords: Autoimmune hepatitis, Hepatocellular carcinoma, Lymphoma, Malignancies
To access this article, please choose from the options below
☆ The authors declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.
PII: S0168-8278(08)00699-5
doi:10.1016/j.jhep.2008.08.022
© 2008 European Association for the Study of the Liver. Published by Elsevier Inc. All rights reserved.
